Tuesday, April 8, 2014

Lawsuit between Walmart and Visa

The recent drop of 2.7% is due to the lawsuit between Walmart and Visa Inc. Walmart has sued Visa Inc. for a total of $5 billion USD. This is with regard to a allegedly high amount of card swipe fees taken by Visa during the various retail transactions of Walmart. There was no immediate response from Visa Inc. for this lawsuit. This case is based on strong precedent set by the $5.7 billion settlement Visa and MasterCard agreed in a class-action regarding the same matter. Meanwhile, Walmart has announced that it will switch its branded cards from Discover to MasterCard. This is a win for MasterCard and a missed opportunity for Visa Inc. In addition, Visa Europe is expected to slice down the rate that it charges for card transactions in Poland. It is also known as the interchange rate.The increase has been done of 0.5%, from 1.2 to 1.3 percent. The reduction will be effective from 1stof July. As more and more retailers seek direct entries into the mobile payment industry, big retailers no longer want to share as much of their thin profit margins in paying electronic-transaction fees. They see mobile-based digital wallets as a way of circumventing Visa and its peers to keep more of their revenue for themselves.

In the Russian side, the suspension has been withdrawn, Russia has decided to have its own domestic payment system within six months to become more self dependent in the future. It is hard for Russian to start a new payment system, since Visa and MasterCard hold the lion’s share of plastic card market in
Russia.So it seems difficult for Russia’s planned domestic payment service to compete against these card giants.

Monday, April 7, 2014

Another FDA Approval for Integra LifeSciences


Integra LifeSciences has received FDA clearance for their Camino Flex Ventricular Catheter.  This catheter is designed to be used with Integra’s Camino Monitor which was approved last year and is already used in over 800 centers across the United States. This device is used with magnetic resonance imaging (MRI scans) and gives clinicians a more advanced system that can monitor ICP independently even when CSF flow cannot be measured, unlike competing catheters which depend on CSF flow.  Integra is not new to the neurosurgery industry, but has an already existing product line that consists of: cranial access kits and CSF drainage systems.  Their neurosurgery product line is their second largest segment, next to orthopedics, and reported $278,992 in fourth quarter revenue in 2013 coming from their neurosurgery segment.  This figure represents approximately one third of their total revenue for the respected quarter.

Friday, April 4, 2014

Google shares split 2 to 1

Google's new class C shares began trading yesterday April 3rd and are off to a rocky start. The shares were in the green by around half a percent yesterday but a sharp market-wide sell off sent them tumbling over 3 percent today April 4th. The stock had quite a rough few weeks after hitting highs above 1200 (600) a share and are down to the low 550s. The company really had quite a run so the profit taking is no surprise. The class A shares (GOOGL) have been outperforming the Class Cs (GOOG) at this point, something Google's management claims Class C shareholders will be compensated for after the first year of trading, so we will have to wait and see how that story develops. A few things may be sending the stock down at this point but the main thing on our radar is the fact that Facebook has been taking an increasing amount of mobile ad market-share. A recall has also been issued for Nest Lab's smoke alarms that resulted in a sales halt. Although the issue may take around three months to resolve a drop in the recent acquisition's sales will not have much of an impact. The threats are certainly being explored but Google has so many things up it's sleeve and we plan to hold on to the stock for sure. Google is set to unlock revenue streams beyond its core ad business in a rather long list of different markets. Executives recently discussed offering a fiber internet and phone service, and Chromebook, as well as Chromecast, sales have been strong.  A partnership with eye-wear company Luxottica will also present opportunities for Google Glass. We are especially interested in the Chromebook story considering the recent announced partnership with virtualization software company VMware. The next conference call will be extremely important after a miss last quarter. Investors are going to need to see earnings growth here if the stock is going to carry a lofty P/E multiple above the 30x range. Currently this multiple has actually dropped below 30 to around 29x and further contraction is certainly possible. After considering the serious growth prospects we highly doubt this multiple will drop below 25x.

According to Flurry's recent mobile ad stats,

-Google's services account for 18% of time spent on Android/iOS devices and Facebook is sitting uncomfortably close at 17%
-eMarketer estimated 49% of global mobile ad expenditures went to Google with 17.5% going to Facebook.

Saturday, March 29, 2014

UPDATE ON CITI- SELL TO HALF POSITION

Because of it's rejection of their capital plan, Citi was refused it's request to  raise dividends and share buyback. They do have a month to resubmit the plan and go through the stress tests again, but I believe the chance of them fixing their internal issues to comply with the Fed will take longer.

Many believe this has pushed back their return of capital to shareholders into 2015.  This has led to four firms to downgrade the stock to market-perform, cutting their price targets to $52.

 For this reason, I have decided we should cut to a half position.  We should be able to get out right around our buy-in price. I do believe it's a good idea to keep a half position because of other possible positive catalysts like their upcoming earnings on April 14th, and good vibes from the banking industry overall.


Wednesday, March 26, 2014

Integra LifeSciences Expands Skin and Wound Portfolio


Yesterday, Tuesday, March 25, 2014, Integra LifeSciences launched their new skin and wound product: Integra Wound Matrix (Thin).  It has received 510K clearance from the USFDA and Integra is anticipating a full market release next month after being featured at the American Burn Association Annual Meeting which taking place in Boston this week.  This product expands the opportunities for treatments from their original Integra Wound Matrix and can now be useful on more “complex anatomical sites” than the original version.  The treatments of the product includes, but is not limited to: second degree burns, various types of wounds, and various types of ulcers.  It can be purchased in a number of different sizes, and has a shelf-life of one year.  Integra closed today at $45.26 representing a 12% upside from our original buy price of $40.41.
Today after the market closed Citigroup's Capital Plan was rejected by the Fed.  This was part of the Comprehensive Capital Analysis and Review (CCAR).  In it's statement, the Fed objected it because of qualitative, not quantitative reasons. These include  deficiencies in it's capital planning processes which had been identified by supervisors and hadn't sufficiently improved in the eyes of the Fed.  Specifically Citi's ability to project revenue and losses under extremely stressful scenarios, and internal stress testing that adequately reflect it's full range of businesses and exposure.   The Fed noted "Citigroup has made considerable progress in improving its general risk-management and control practices over the years".

In the capital plan they requested a $6.4 Billion share repurchase and an increased  quarterly dividend to $.05.  They will not be allowed to increase either, but will continue with their $1.2 billion buyback and $.01 dividend. They will be given 30 days to resubmit their plan, hopefully complying with the Fed.

Although they performed poorly in the stress test, they were still above the Fed's minimum 5% Tier 1 common ratio, at 6.5%.  Citi is clearly being subjected to the highest standards because of it's global scale and complex operations.  Citi remains one of the best-capitalized financial institutions in the world.  In their statement they said they will work closely with the Fed to bring their capital planning process in line with their qualitative standards.

The stock is down 5.6% in after hours, which diminishes the return since our buy-in.

Precision Castparts to Acquire Aerospace Dynamics



March 20th, Precision Castparts Corp. (PCP) agreed to acquire Aerospace Dynamics International (ADI) from The Marvin Group for $625 million.  ADI is a major player in the aerospace supplier industry with differentiating expertise in hard metal machining, large complex components, and critical assemblies.  Operating out of Valencia, California with a staff of 625 employees ADI has competitive positions across high growth platforms including the Airbus A350.

The cash acquisition will be treated as an acquisition of assets for tax purpose and will be immediately accretive to earnings.  The transaction is expected to be completed during the first quarter of fiscal 2015—after the scrutiny of regulatory approvals—after which ADI will be reported as part of PCP’s Airframe Products segment.  This acquisition goes hand-in-hand with PCP’s historical trend of acquisition binges.  PCP has a good record of instilling better management in the acquired companies which translates to stronger margins.  That being said, I do not believe PCP is dependent on acquisitions for earnings growth or is too bloated with acquisitions to have a sustained management advantage.